iodomethyl 2-naphthoate | 117941-79-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: iodomethyl 2-naphthoate
• 英文别名: 2-naphthylcarbonyloxymethyl iodide；Iodomethyl naphthalene-2-carboxylate
• CAS: 117941-79-4
• 化学式: C₁₂H₉IO₂
• 分子量: 312.107
• InChiKey: BCUXZNFHUQJVRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  iodomethyl 2-naphthoate 在 Amberlite IRA-400 Cl(-) exchange resin 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 2-<(hydroxyimino)methyl>-3-methyl-2-<(2'-naphthoyloxy)methyl>imidazolium chloride
  参考文献：
  名称：

  Quaternary salts of 2-[(hydroxyimino)methyl]imidazole. 2. Preparation and in vitro and in vivo evaluaton of 1-(alkoxymethyl)-2-[(hydroxyimino)methyl]-3-methylimidazolium halides for reactivation of organophosphorus-inhibited acetylcholinesterases

  摘要：

  A series of structurally related mono- and bis-1,3-disubstituted 2-[(hydroxyimino)methyl]imidazolium halides were evaluated in vitro for their ability to reactivate electric eel, bovine, and human erythrocyte (RBC) acetylcholinesterases (AChE) inhibited by ethyl p-nitrophenyl methylphosphonate (EPMP) and 3,3-dimethyl-2-butyl methyl-phosphonofluoridate (soman, GD). All new compounds were characterized for (hydroxyimino)methyl acid dissociation constant, nucleophilicity, octanol-buffer partition coefficient, reversible AChE inhibition, and kinetics of reactivation of EPMP-inhibited AChEs. For GD-inhibited AChEs, maximal reactivation was used to compare compounds since rapid phosphonyl enzyme dealkylation "aging" complicated interpretation of kinetic constants. For comparison, we also evaluated three known pyridinium therapeutics, 2-PAM, HI-6, and toxogonin. In vivo evaluation in mice revealed that when selected imidazolium compounds were coadministered with atropine sulfate, they were effective in providing lifesaving protection against both GD and EPMP challenges. This was a major accomplishment in the search for effective anticholinesterase therapeutics--the synthesis and preliminary evaluation of the first new monoquaternary soman antidotes with potencies superior to 2-PAM. Significantly, there was an apparent inverse relationship between in vitro and in vivo results; the most potent in vivo compounds proved to be the poorest in vitro reactivators. These results suggested that an alternative and possibly novel antidotal mechanism of protective action may be applicable for the imidazolium aldoximes. Selected compounds were also evaluated for their inhibition of AChE phosphorylation by GD and antimuscarinic and antinicotinic receptor blocking effects.

  DOI：

  10.1021/jm00122a034
• 作为产物：
  描述：

  chloromethyl 2-naphthoate 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 4.0h， 生成 iodomethyl 2-naphthoate
  参考文献：
  名称：

  Quaternary salts of 2-[(hydroxyimino)methyl]imidazole. 2. Preparation and in vitro and in vivo evaluaton of 1-(alkoxymethyl)-2-[(hydroxyimino)methyl]-3-methylimidazolium halides for reactivation of organophosphorus-inhibited acetylcholinesterases

  摘要：

  A series of structurally related mono- and bis-1,3-disubstituted 2-[(hydroxyimino)methyl]imidazolium halides were evaluated in vitro for their ability to reactivate electric eel, bovine, and human erythrocyte (RBC) acetylcholinesterases (AChE) inhibited by ethyl p-nitrophenyl methylphosphonate (EPMP) and 3,3-dimethyl-2-butyl methyl-phosphonofluoridate (soman, GD). All new compounds were characterized for (hydroxyimino)methyl acid dissociation constant, nucleophilicity, octanol-buffer partition coefficient, reversible AChE inhibition, and kinetics of reactivation of EPMP-inhibited AChEs. For GD-inhibited AChEs, maximal reactivation was used to compare compounds since rapid phosphonyl enzyme dealkylation "aging" complicated interpretation of kinetic constants. For comparison, we also evaluated three known pyridinium therapeutics, 2-PAM, HI-6, and toxogonin. In vivo evaluation in mice revealed that when selected imidazolium compounds were coadministered with atropine sulfate, they were effective in providing lifesaving protection against both GD and EPMP challenges. This was a major accomplishment in the search for effective anticholinesterase therapeutics--the synthesis and preliminary evaluation of the first new monoquaternary soman antidotes with potencies superior to 2-PAM. Significantly, there was an apparent inverse relationship between in vitro and in vivo results; the most potent in vivo compounds proved to be the poorest in vitro reactivators. These results suggested that an alternative and possibly novel antidotal mechanism of protective action may be applicable for the imidazolium aldoximes. Selected compounds were also evaluated for their inhibition of AChE phosphorylation by GD and antimuscarinic and antinicotinic receptor blocking effects.

  DOI：

  10.1021/jm00122a034

文献信息

• Carbapenem derivatives
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：US06458780B1

  公开（公告）日：2002-10-01

  Disclosed is a novel carbapenem derivative having a substituted imidazo[5,1-b]thiazole group at the 2-position on the carbapenem ring have high anti-microbial activities against &bgr;-lactamase producing bacteria, MRSA, resistant-Pseudomonas aeruginosa, PRSP, enterococci, and influenza, and high stabilities to DHP-1. According to the present invention, there is provided a compound represented by the formula (I), or a pharmacologically acceptable salt thereof or an ester at the 3-position on the carbapenem ring thereof:

  公开了一种新的碳青霉烯衍生物，其在碳青霉烯环的2位置具有取代的咪唑[5,1-b]噻唑基团，对产生β-内酰胺酶的细菌、耐甲氧西林金黄色葡萄球菌(MRSA)、抗假单胞菌属铜绿假单胞菌、肺炎链球菌(PRSP)、肠球菌和流感具有高的抗菌活性，并对DHP-1具有高稳定性。根据本发明，提供了一种由公式(I)表示的化合物，或其药理上可接受的盐，或其碳青霉烯环上3位置的酯。
• Novel carbapenem derivatives
  申请人：——

  公开号：US20030149016A1

  公开（公告）日：2003-08-07

  Disclosed is a novel carbapenem derivative having a substituted imidazo[5,1-b]thiazole group at the 2-position on the, carbapenem ring have high anti-microbial activities against &bgr;-lactamase producing bacteria, MRSA, resistant- Pseudomonas aeruginosa , PRSP, enterococci, and influenza, and high stabilities to DHP-1. According to the present invention, there is provided a compound represented by the formula (I), or a pharmacologically acceptable salt thereof or an ester at the 3-position on the carbapenem ring thereof: 1

  本发明公开了一种新型碳青霉烯衍生物，其在碳青霉烯环上的2位上具有取代咪唑[5,1-b]噻唑基团，对β-内酰胺酶产生的细菌、MRSA、耐药性假单胞菌、PRSP、肠球菌和流感病毒具有高抗菌活性，并对DHP-1具有高稳定性。根据本发明，提供了由式(I)表示的化合物，或其在碳青霉烯环上的3位处的药理学上可接受的盐或酯：1。
• NOVEL CARBAPENEM DERIVATIVES
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1101766A1

  公开（公告）日：2001-05-23

  Disclosed is a novel carbapenem derivative having a substituted imidazo[5,1-b]thiazole group at the 2-position on the carbapenem ring have high anti-microbial activities against β-lactamase producing bacteria, MRSA, resistant-Pseudomonas aeruginosa, PRSP, enterococci, and influenza, and high stabilities to DHP-1. According to the present invention, there is provided a compound represented by the formula (I), or a pharmacologically acceptable salt thereof or an ester at the 3-position on the carbapenem ring thereof:

  本发明公开了一种新型碳青霉烯类衍生物，该衍生物的碳青霉烯环上 2 位具有取代的咪唑并[5,1-b]噻唑基团，对产β-内酰胺酶细菌、MRSA、耐药铜绿假单胞菌、PRSP、肠球菌和流感具有高抗微生物活性，对 DHP-1 具有高稳定性。根据本发明，提供了一种由式（I）代表的化合物，或其药理学上可接受的盐，或其碳青霉烯环上 3 位的酯：
• US6458780B1
  申请人：——

  公开号：US6458780B1

  公开（公告）日：2002-10-01
• US6677331B2
  申请人：——

  公开号：US6677331B2

  公开（公告）日：2004-01-13